“We are delighted to have reached an agreement on the path towards regulatory approval for this important contribution to the treatment of Wilson’s Disease”, says Dr. Walberg, CEO of Medical Need, and continues: “Combining the in-depth product knowledge of Tactic Pharma with the vast industry experience and financial strength of Health Cap plus Medical Need’s expertise in the field of orphan and niche pharmaceuticals creates a very strong team. Like many orphan conditions, Wilson’s disease is still an area with clear unmet medical needs and DecuprateTM has the potential to add significant value for the Wilson’s disease patients.

Please note that the email address you provide when contacting Medical Need are processed electronically by Medical Need. We will not store your address in any register and we will not use your address in other way than to answer any question initiated by sending us an email. We will not store any personnel information except in the case of reporting a possible adverse event or complaint, see more info under Safety and complaints.